Sorafenib and azacitidine as salvage therapy for relapse of <scp>FLT</scp>3‐<scp>ITD</scp> mutated <scp>AML</scp> after allo‐<scp>SCT</scp> - Concepedia

Concepedia

Publication | Closed Access

Sorafenib and azacitidine as salvage therapy for relapse of <scp>FLT</scp>3‐<scp>ITD</scp> mutated <scp>AML</scp> after allo‐<scp>SCT</scp>

47

Citations

24

References

2016

Year

Christina Rautenberg, Kathrin Nachtkamp, Ariane Dienst, Pia Verena Schmidt, Claudia Heyn, Mustafa Kondakci, Ulrich Germing, Rainer Haas, Guido Kobbe, Thomas Schroeder

European Journal Of Haematology

Abstract

Taken together, the combination of sorafenib, Aza, and DLI shows promising efficacy and deserves further evaluation in larger patient groups.

References

	Year	Citations

Page 1